- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
DeepLook, Inc.’s Segmentation and Measurement Tool Captures FDA Clearance
One-click tool is designed to deliver precision consistently across all imaging modalities.
Connecticut-based software firm DeepLook, Inc., announced Thursday it has received U.S. Food & Drug Administration approval for DL Precise, its one-click segmentation and measurement tool.
This tool is designed to automate segmentation and measurement of suspicious findings across all imaging modalities, potentially improving workflow and reporting precision. Still, company officials noted, users can maintain full control and modify any automated measurement if they choose.
At left, one-click segmentation and measurement rendered by DL Precise. At right, DL Precise uses vivid color to illustrate segmentation.
Credit: DeepLook
DL Precise uses deterministic algorithms to contour object margins and measure long and short dimension axes, area, and estimated volume. With its single-click activation, it side-steps the complex, time-consuming manual set-up that frequently comes with current semi-automatic segmentation tools.
Not only does DL Precise work with any DICOM image and on all 510(k)-cleared viewers, but its patented technology can also be used universally with mammography, ultrasound, CT, and MRI, and the data captured can be fed directly into structured reports, making image comparisons across modalities easier. It can also be adapted to each viewer interface for easy PACS integration, according to company data.
DeepLook also has plans for future decision-support and diagnostic products based on radiomic data.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
What Emerging CT Research Reveals About Obesity and Post-Op Survival for Non-Small Cell Lung Cancer
January 29th 2025For those without low skeletal muscle mass on CT and myosteatosis, obese patients have a 23 percent lower risk of death than non-obese patients after undergoing curative resection for non-small cell lung cancer, according to newly published research.
